ADVANCEMENTS IN TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH A FOCUS ON TYROSINE KINASE INHIBITORS IMMUNE CHECKPOINT INHIBITORS AND THEIR COMBINATION STRATEGIES

Metastatic renal cell carcinoma (mRCC) presents a significant challenge in oncology, necessitating advancements in targeted therapies. This paper examines the role of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) in mRCC treatment, focusing on their combination strategies. Recent studies suggest that combining these therapies enhances patient outcomes by targeting multiple oncogenic pathways simultaneously. This review explores clinical trial outcomes from 2023, providing statistical data, survival rates, and adverse effects of these treatments. Future perspectives on optimizing therapy and overcoming resistance mechanisms are also discussed.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-02-03
DOI
https://doi.org/10.5281/zenodo.14792299
Primary Topic
Spacecraft Dynamics and Control
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ADVANCEMENTS IN TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH A FOCUS ON TYROSINE KINASE INHIBITORS IMMUNE CHECKPOINT INHIBITORS AND THEIR COMBINATION STRATEGIES

Zenodo (CERN European Organization for Nuclear Research)
Spacecraft Dynamics and Control
article

ADVANCEMENTS IN TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH A FOCUS ON TYROSINE KINASE INHIBITORS IMMUNE CHECKPOINT INHIBITORS AND THEIR COMBINATION STRATEGIES

article en

Abstract

Metastatic renal cell carcinoma (mRCC) presents a significant challenge in oncology, necessitating advancements in targeted therapies. This paper examines the role of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) in mRCC treatment, focusing on their combination strategies. Recent studies suggest that combining these therapies enhances patient outcomes by targeting multiple oncogenic pathways simultaneously. This review explores clinical trial outcomes from 2023, providing statistical data, survival rates, and adverse effects of these treatments. Future perspectives on optimizing therapy and overcoming resistance mechanisms are also discussed.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 46%
Spacecraft Dynamics and Control
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

ADVANCEMENTS IN TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH A FOCUS ON TYROSINE KINASE INHIBITORS IMMUNE CHECKPOINT INHIBITORS AND THEIR COMBINATION STRATEGIES · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS